The report "Genotyping Assay Market by Product & Services (Kits, Instruments,Bioinformatics), Technology (PCR, Sequencing, Microarray), Application (Pharmacogenomics, Animal Genetics), End User (PharmaBiotech Companies, Diagnostic Labs) - Global Forecast to 2029", is projected to reach USD 37.1 billion by 2029 from USD 19.4 billion in 2024, at a CAGR of 13.8% during the forecast period.

Browse 444 market data Tables and 59 Figures spread through 388 Pages and in-depth TOC on "Genotyping Assay Market by Product & Services (Kits, Instruments,Bioinformatics), Technology (PCR, Sequencing, Microarray), Application (Pharmacogenomics, Animal Genetics), End User (PharmaBiotech Companies, Diagnostic Labs) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/genotyping-market-249958595.html

It is anticipated that the market would develop due to advancements in technology and the declining cost of DNA sequencing. The market's recent rise has also been impacted by the rising incidence of hereditary illnesses. Moreover, genotyping is now a key component of personalized medicine, drug development, and discovery.

“Reagents & Kits segment accounted for the highest CAGR”

By product & service, the market is primarily segmented into reagents and kits, instruments, GENOTYPING ASSAY services, and bioinformatics. The reagents & kits segment accounted for the largest share of the Genotyping assay in 2023. The significant portion of this market can be ascribed to the availability of a broad variety of reagents, the rising demand for reagents as a result of the global increase in GENOTYPING ASSAY test volumes, and the comparatively lower initial investment needed to implement reagents and kits for GENOTYPING Assay in pharmacies and diagnostic facilities.

“The polymerase chain reaction (PCR) segment accounted for the market share in the genotyping assay market, by technology, during the forecast period”

By technology, the market is primarily segmented into polymerase chain reaction (PCR), microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF), and other technologies (in situ hybridization and allele-specific oligonucleotides). The PCR segment accounted for the largest share of the GENOTYPING ASSAY technology market in 2023. The main factors propelling the growth of the PCR market are the introduction of new technologies like reverse transcriptase PCR, nested PCR, hot-start PCR, allele-specific PCR, and multiplex PCR; technological developments in PCR instruments and reagents; and the growing use of PCR technologies in the domains of genetics, prenatal testing, forensics, and personalized medicine.

“Pharmacogenomics segment accounted for the highest share”

By application, the market is primarily segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment accounted for the largest share of the GENOTYPING ASSAY applications market in 2023. The need to lower the overall cost of medication development for pharmaceutical companies and the growing demand for pharmacogenomics to research adverse drug reactions (ADRs) in clinical trials are the primary drivers of growth in this market. The pharmacogenomics genetyping test is predicted to grow due to various factors, including the rising need for personalized medication, the rise in hereditary and life-threatening disorders, and ongoing research on effective and alternative drug delivery techniques.

“Biopharmaceutical & pharmaceutical companies segment accounted for the highest share”

By end user, the market is primarily segmented into biopharmaceutical & pharmaceutical companies, diagnostic laboratories, academic & research institutes, and other end users. The biopharmaceutical & pharmaceutical companies segment accounted for the largest share of the GENOTYPING ASSAY end-user market in 2023. The significant market share of this industry may be ascribed to the growing need for pharmacogenomics in the drug research and discovery process, the introduction of new products, and FDA recommendations to incorporate pharmacogenomics studies and GENOTYPING ASSAY in the drug discovery process. Furthermore, growing partnerships and funding for pharmacogenomics research further support the expansion of this market sector for GENOTYPING ASSAY.

“North America aimed for the largest share of the genotyping assay market”.

The global genotyping assay market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. North America is the largest regional market for genotyping assays. North America is the largest regional market for cancer biomarkers. This regional segment's dominance can be attributed to a number of factors, including the growing use of technologically sophisticated GENOTYPING ASSAY products, the availability of government and private funding for research projects based on GENOTYPING ASSAY, the expanding use of GENOTYPING ASSAY in pharmacogenomics, rising investments in DNA-based testing, the growing uptake of NGS, and the presence of major market players in the area.

The major players leading in this market are Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher Corporation (US), QIAGEN (Netherlands), Eurofins Scientific (Luxembourg), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Merck KGAA (Germany), Agilent Technologies (US), Revvity Inc. (US), Standard Bio Tools (US), PacBio (US), GENEWIZ Inc. (US), Luminex Corporation (Diasorin Company) (US), Oxford Nanopore Technologies Plc (UK), GenScript (US), Takara Bio Inc. (Japan), New England Biolabs (US),  Promega Corporation (US), Tecan Trading AG (Switzerland), Genotypic Technology Pvt. Ltd. (India), BGI GROUP (China), Novogene Co., Ltd. (China),  Paragon Genomics, Inc. (US),  NeoGenomics Laboratories (US).

Don’t miss out on business opportunities in Genotyping Assay Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com